Skip to Content
Biotechnology and health

Stanford has cleared its professors over the CRISPR baby scandal

April 17, 2019

Three Stanford scientists did not “directly participate” in a project to create the first CRISPR babies, the New York Times reports.

The context: The inquiry by Stanford University, which was first revealed by MIT Technology Review, was tasked with looking into what several high-profile faculty members knew about a project by Chinese researcher He Jiankui He to create the world’s first gene-edited babies (here is a brief summary of everything we know about that experiment so far).

The report: The university probe cleared three of its professors of wrongdoing, most notably Stephen Quake, a biophysicist who was He’s advisor when he was doing postdoctoral research at Stanford. Stanford said Quake did not directly help He with his subsequent gene-editing experiment. In a statement, the university said none of the professors had any financial or organizational ties to the work. In fact, the report claims, Quake tried to persuade He to abandon the project, and to follow proper protocols after he insisted on pursuing it.

The wider context: Since He announced the birth of the gene-edited twins Lulu and Nana in November, questions have been raised within the scientific community about who knew about the work, and what they should have done about it. Although this investigation is closed, questions over what scientists should do when confronted with ethically questionable research remain.

Sign up here to get your dose of the latest must-read news from the world of emerging tech in our daily newsletter The Download.

Deep Dive

Biotechnology and health

How scientists traced a mysterious covid case back to six toilets

When wastewater surveillance turns into a hunt for a single infected individual, the ethics get tricky.

An AI-driven “factory of drugs” claims to have hit a big milestone

Insilico is part of a wave of companies betting on AI as the "next amazing revolution" in biology

The quest to legitimize longevity medicine

Longevity clinics offer a mix of services that largely cater to the wealthy. Now there’s a push to establish their work as a credible medical field.

There is a new most expensive drug in the world. Price tag: $4.25 million

But will the latest gene therapy suffer the curse of the costliest drug?

Stay connected

Illustration by Rose Wong

Get the latest updates from
MIT Technology Review

Discover special offers, top stories, upcoming events, and more.

Thank you for submitting your email!

Explore more newsletters

It looks like something went wrong.

We’re having trouble saving your preferences. Try refreshing this page and updating them one more time. If you continue to get this message, reach out to us at customer-service@technologyreview.com with a list of newsletters you’d like to receive.